智能驾驶技术用于非侵入性检测与年龄相关的认知衰退
Peter Serhan1,2,3, Shaun Victor2, Oscar Osorio Perez2,4
1School of Electrical, Computer and Energy Engineering, Arizona State University, Tempe, AZ 85281, USA.
Sensors (Basel, Switzerland)
|January 8, 2025
概括
一个新的智能驾驶系统使用人工智能和生物传感器来检测轻度认知障碍 (MCI) 的早期迹象,这是阿尔茨海默病 (AD) 和相关痴呆症 (ADRD) 的前体. 这项技术旨在进行早期检测,以便及时进行生活方式干预.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 生物医学工程 生物医学工程
背景情况:
- 阿尔茨海默病和相关痴呆症 (ADRD) 构成了全球重大健康挑战,预计将影响数百万人.
- 轻度认知障碍 (MCI) 是痴呆症的关键前体,为干预提供了一个窗口.
- 目前的MCI检测方法往往不常见,无法捕捉微妙的认知衰退.
研究的目的:
- 为早期发现神经退行性疾病推出一种新,不引人注目的,经济的智能驾驶系统.
- 介绍一个集驾驶性能和生物识别数据用于认知评估的系统的初步开发和验证.
- 为智能驾驶设备和应用程序奠定基础,以广泛检测MCI.
主要方法:
- 开发一个多模生物传感阵列 (MMS).
- 整合人工智能算法来分析驾驶性能和驾驶员的生物识别.
- 专注于不引人注目的车载监控,以获得认知功能洞察力.
主要成果:
- 智能驾驶系统展示了通过驾驶和生物识别数据检测神经退行性疾病早期阶段的潜力.
- 该系统为不引人注目的认知监测提供了一种新的方法.
- 这项研究是迈向完全集成和验证的MCI检测系统的第一步.
结论:
- 智能驾驶系统为早期MCI检测提供了一个有希望的,经济的和不引人注目的方法.
- 计划通过全面的试点研究进行进一步验证,以确定其有效性.
- 这项技术可以促进及时干预,延迟或预防痴呆症的进展.
关键词:
阿尔茨海默氏症 (AD) 是一种疾病.早期发现阿尔茨海默氏症轻度认知障碍 (MCI) 是一种轻度认知障碍.智能驾驶系统 智能驾驶系统认知健康监测 认知健康监测多模态传感阵列 (MMS) 是一种多模态传感阵列.更多相关视频
06:58Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
7.3K
11:21Methodology for Establishing a Community-Wide Life Laboratory for Capturing Unobtrusive and Continuous Remote Activity and Health Data
Published on: July 27, 2018
8.2K
相关概念视频
01:30Cognitive Development During Adulthood
50
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
50
01:30Dementia
94
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
94
01:26Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95